Today: 9 June 2026
Joby Aviation stock slides after $1.2 billion deal; dilution and hedging now in focus
30 January 2026
2 mins read

Joby Aviation stock slides after $1.2 billion deal; dilution and hedging now in focus

New York, Jan 29, 2026, 20:42 EST — Market closed

  • Joby Aviation shares dropped roughly 17% following the announcement of an upsized stock-and-convertible offering.
  • The deal comes to around $1.2 billion, with $600 million in convertible notes maturing in 2032.
  • Traders are now focused on deal settlement set for Feb. 2 and the amount of new supply the market must absorb.

Joby Aviation shares fell sharply on Thursday, dropping 16.8% to $11.14. The electric air taxi maker unveiled a bigger-than-anticipated fundraising deal, introducing more stock and a new tranche of convertible debt.

Timing is key as Joby continues investing to certify and produce its aircraft. New funding stretches the runway but dilutes existing shareholders and might attract short-term hedge flows betting against the stock.

Investors often lash out at early-stage aerospace companies that aggressively tap markets, even if the reasons are clear: costs for certification, factories, and prepping for commercial service pile up well before any significant revenue appears.

Joby priced $600 million of 0.75% convertible senior notes due 2032, along with 52,863,437 common shares at $11.35 each, boosting the deal size from the earlier $1 billion target. The company also outlined a separate “delta offering” of 5,286,343 borrowed shares led by Morgan Stanley, aimed at helping some note buyers hedge; Joby won’t receive proceeds from that sale. The offerings are set to settle on Feb. 2, with underwriters holding 30-day options to pick up additional notes and shares. Joby Aviation, Inc.

Convertible notes are debt instruments that can later convert into stock, typically at a predetermined price. For Joby, that initial conversion price was set around $14.19 a share—a premium to the stock offering price. This setup can lower the coupon cost but still risks equity dilution if the share price bounces back.

Traders are zeroing in on the hedging angle. Joby’s prospectus lays out how delta shares get borrowed and sold to help “convertible arbitrage” investors hedge—often by shorting the stock against the notes. This setup can weigh on the shares until the fresh supply gets absorbed. SEC

Joby is expanding its manufacturing capacity as it moves closer to certification. In a Jan. 7 filing related to an Ohio facility purchase, CEO JoeBen Bevirt stated, “This site will not only support our near-term plan to double production,” highlighting the company’s push to shift from engineering to full-scale manufacturing. Joby Aviation, Inc.

Shares of other U.S.-listed eVTOL companies slipped as well, but Joby’s decline was notably sharper following its larger capital raise.

But the deal isn’t one-sided. Despite a capped-call structure meant to limit dilution from conversions, new shares start trading right away. The note-and-hedge arrangement might prolong the technical selling pressure. If certification drags or production ramps slower than anticipated, doubts will resurface about how frequently Joby will have to tap the markets again.

Traders will be focused on whether JOBY can find footing after Thursday’s sharp drop and how it performs as the Feb. 2 settlement approaches. Investors are also keeping tabs on the upcoming earnings report — listed on Investing.com for Feb. 25, 2026 — looking for updates on cash burn and certification timelines.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Accenture stock slides 3% as new share award pool wins approval — what investors watch next
Previous Story

Accenture stock slides 3% as new share award pool wins approval — what investors watch next

GSK share price dips in London as Exdensur rollout and Feb 4 results loom
Next Story

GSK share price dips in London as Exdensur rollout and Feb 4 results loom

Go toTop